Molecular weight
389.4 Da
FDA-approved ED, BPH, pulmonary arterial hypertension (Adcirca). Longevity research: weekly low-dose tadalafil shows cardiovascular protection, reduced fibrosis, improved exercise capacity in aging models.
Selective PDE5 (phosphodiesterase type 5) inhibitor. Prevents breakdown of cGMP → sustained smooth muscle relaxation → vasodilation. 36h half-life vs 4–6h sildenafil. Emerging longevity research: PDE5 inhibition reduces cardiac fibrosis, improves mitochondrial function, reduces inflammatory cytokines. Weekly low-dose cardiovascular research ongoing.
36h half-life; PDE5 inhibition; cGMP elevation; FDA-approved (ED/BPH/PAH); cardiovascular protection research; cardiac fibrosis reduction.
Research data is not a treatment plan. If you are considering Tadalafil, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.
Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.Interactive tools for this compound:
Reconstitution calculator · Full deep dive · Peptide fundamentals